On November 12, the cell therapy concept stocks experienced a notable surge in the afternoon session. Canature Health Technology Co.,Ltd. and Zhongyuan Union Cell & Gene Engineering Corp. hit the daily limit-up, following earlier limit-ups by Nanjing Xinbai (Rights Protection) and Jiumen Health. Sanyuan Gene and Leadman Biochemistry rose over 10%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments